Characteristic Study ID |
Intervention(s) and comparator(s) | Randomised [N] | Deaths [n/N (%)] | All adverse events [n/N (%)] | Severe/serious adverse events [n/N (%)] | Discontinued study due to adverse events [n/N (%)] |
Avenell 2012 | I1: vitamin D₃ | 2649 | 836/2649 (31.6) | 363/2649 (13.7) | ‐ | ‐ |
C1: matched placebo | 2643 | 881/2643 (33.3) | 386/2643 (14.6) | |||
all: | 5292 | 33 (0.6) | ||||
Bolton‐Smith 2007 | I1: vitamin D₃ plus calcium | 62 | 0/62 (0) | ‐ | ‐ | ‐ |
C1: matched placebo | 61 | 1/60 (1.7) | ||||
all: | 123 | |||||
Brunner 2011 | I1: vitamin D₃ plus calcium | 18,176 | 744/18,176 (4.1) | 449/18176 (2.5) | 449/18,176 (2.5) | ‐ |
C1: matched placebo | 18,106 | 807/18,106 (4.5) | 381/18106 (2.1) | 381/18,106 (2.1) | ||
all: | 36,282 | |||||
Daly 2008 | I1: calcium‐vitamin D₃‐fortified milk plus calcium | 85 | 1/85 (1.2) | 9/85 (10.6) | 9/85 (10.6) | 9/85 (10.6) |
C1: no intervention | 82 | 0/82 (0) | 2/82 (2.4) | 2/82 (2.4) | 2/82 (2.4) | |
all: | 167 | |||||
Gallagher 2001 | I1: calcitriol | 123 | 2/123 (1.6) | 87/123 (71.0) | 55/123 (45.0) | ‐ |
C1: matched placebo | 123 | 1/123 (0.8) | (56/123 (45.5) | 46/123 (37.0) | ||
all: | 246 | |||||
Glendenning 2012 | I: cholecalciferol 150,000 3‐monthly | 353 | 2/353 (0.6) | 24/353 (6.8) | 19/353 (5.4) | ‐ |
C: placebo vitamin D 3‐monthly | 333 | 0/333 (0) | 21/333 (6.3) | 15/333 (4.5) | ||
all: | 686 | |||||
Grady 1991 | I: calcitriol | 50 | 1/50 (2) | 7/50 (14.0) | 7/50 (14.0) | ‐ |
C: placebo vitamin D | 48 | 0/48 (0) | 2/48 (4.2) | 2/48 (4.2) | ||
all: | 98 | |||||
Janssen 2010 | I: vitamin D₃ plus calcium | 36 | 0/36 (0) | ‐ | ‐ | ‐ |
C: matched placebo vitamin D₃ plus calcium | 34 | 0/34 (0) | ||||
all: | 70 | |||||
Komulainen 1999 | I: vitamin D₃ plus calcium | 116 | 0/116 (0) | ‐ | 5/116 (4.3) | ‐ |
C: placebo | 116 | 1/116 (0.9) | 4/116 (3.4) | |||
all: | 232 | |||||
Lappe 2007 | I1: vitamin D₃ plus calcium | 446 | 4/446 (0.9) | 1/446 (0.2) | 13/446 (2.9) | ‐ |
I2: calcium plus vitamin D placebo | 733 | 18/733 (2.5) | 4/733 (0.5 | 20/733 (2.7) | ||
all: | 1179 | |||||
Larsen 2012 | I1: vitamin D₃ | 65 | 2/65 (3.1) | 0/65 (0.0) | 2/65 (3.1) | 1/65 (1.5) |
C1: matched placebo vitamin D | 65 | 0/65 (0.0) | 0/65 (0.0) | 0/65 (0.0) | 0/65 (0.0) | |
all: | 130 | |||||
Murdoch 2012 | I1: vitamin D₃ | 161 | 0/161 (0) | 700/161 | 21/161 (13) | ‐ |
C1: matched placebo vitamin D | 161 | 0/161 (0) | 792/161 | 19/161 (11.8) | ||
all: | 322 | |||||
Ott 1989 | I1: vitamin D3 plus calcium | 43 | 0/43 (0) | 11/43 (25.6) | ‐ | ‐ |
C1: matched placebo vitamin D plus calcium | 43 | 1/43 (2.3) | 1/43 (2.3) | |||
all: | 86 | |||||
Prince 2008 | I1: vitamin D₂2 plus calcium | 151 | 0/151 (0) | ‐ | ‐ | ‐ |
C1: matched placebo tablet of vitamin D plus calcium | 151 | 1/151 (0.7) | ||||
all: | 302 | |||||
Sanders 2010 | I1: vitamin D₃ | 1131 | 40/1131 (3.5) | 223/1131 (19.7) | 244/1131 (19.7) | ‐ |
C1: matched placebo tablet | 1127 | 47/1127 (4.2) | 201/1127 (17.8) | 207/1127 (17.8) | ||
all: | 2258 | |||||
Trivedi 2003 | I1: vitamin D₃ | 1345 | 224/1345 (16.7) | ‐ | ‐ | ‐ |
C1: matched placebo vitamin D | 1341 | 247/1341 (18.4) | ||||
all: | 2686 | |||||
Witham 2013 | I1: vitamin D₃ | 80 | 0/80 (0) | 18/80 (22.5) | 11/80 (13.7) | 0/80 (0) |
C1: matched placebo vitamin D | 79 | 1/79 (1.3) | 21/79 (26.6) | 13/79 (16.5) | 0/79 (0) | |
all: | 159 | |||||
Wood 2012 | I1: vitamin D₃ | 203 | 0/203 (0) | 32/203 (15.8) | 15/203 (7.4) | 11/203 (5.4) |
C1: matched placebo vitamin D | 102 | 0/102 (0) | 20/102 (19.6) | 4/102 (3.9) | 2/102 (2.0) | |
all: | 305 | |||||
"‐" denotes not reported |